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Abstract SDHB mutations are linked to the familial
paraganglioma syndrome type 4 (PGL4), which is associ-
ated with predominantly extra-adrenal disease and has high
metastatic rates. Despite the lower penetrance rates in
carriers of SDHB mutations compared to mutations in other
paraganglioma susceptibility genes, the aggressive behav-
ior of SDHB-linked disease warrants intensive surveillance
to identify and resect tumors early. Patients with similar
SDHB genotypes in whom the PGL syndrome manifests
often exhibit very heterogeneous phenotypes. Tumors can
arise in various locations, and management can be con-
siderably different, depending on tumor site and pathology.
We present a case series of five SDHB mutation carriers
over four generations from the same family to illustrate the
complexities in management.
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Introduction
Paragangliomas (PGLs) are highly vascular tumors arising
in neural crest cells derived from neuroendocrine tissues
associated with the autonomic nervous system and occur
anywhere between the base of the skull and the pelvis [1].
Tumors originating from chromaffin cells of the adrenal
medulla are termed pheochromocytomas. Both germline
and somatic mutations in susceptibility genes, of which
more than a dozen have been identified so far, drive dis-
ease, with familial forms of PGL accounting for at least
40% of all tumors [2]. The paraganglioma/pheochromo-
cytoma susceptibility genes include the nuclear genes
SDHA, SDHB, SDHC and SDHD, which encode the four
subunits of the mitochondrial enzyme succinate dehydro-
genase, involved in Krebs cycle oxidative phosphorylation
and electron transport in the respiratory chain within
mitochondria. The SDHB gene acts as tumor suppressor.
Tumorigenesis is initiated with the ‘second’ hit and loss of
heterozygosity at the SDH subunit gene locus, which leads
to deactivation of the enzyme and impaired mitochondrial
function [1]. Accumulation of the SDH substrate succinate
leads to the stabilization of hypoxia-inducible factor a
(HIFa), precipitating a state of mitochondrial ‘pseudohy-
poxia’ with consequent initiation of angiogenesis, prolif-
eration and cell survival [2]. More recently, the role of the
SDHB gene as a driver of hypermethylation and thus
silencing of key genes involved in neuroendocrine differ-
entiation have been proposed [3].
Mutations of SDHB gene predispose to the familial PGL
syndrome type 4 (PGL4), characterized by a high incidence
of extra-adrenal PGLs and a high rate of metastasis [4].
SDHB mutations carriers are predisposed to developing
other tumors including renal cell carcinoma, gastrointesti-
nal tumors (GIST) and rarely pituitary adenomas [5].
Despite incomplete penetrance, morbidity and mortality
are considerably higher in disease associated with SDHB
mutations than disease linked to other SDHx mutations,
which generally follow a more benign course [5].
Here we report on a unique family with four generations
affected by a SDHB mutation and highlight the hetero-
geneity of presentation and consequent variation in man-
agement strategies tailored to the individual carrier. All
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subjects or their guardians provided informed consent for
this study. The familial mutation was previously reported
in a study of UK subjects [4]. A summary of disease
characteristics is provided in Table 1.
Case series
Subject 1 (index case)
The index case presented at the age of 41 years with a history
of dysphonia, dysphagia and palpitations. Examination
revealed a left vocal cord palsy and a fasciculating tongue
deviating to the left. Imaging identified a mass at the base of
skull involving the left vagus and hypoglossal nerves, with
erosion of the petrous bones into the internal auditory canal.
Staging imaging identified additional bilateral abdominal
lesions adjacent to the aorta and inferior vena cava (IVC). The
left-sided lesion bordered the adrenal gland, and the right-
sided lesion was intimately related to the celiac axis, dis-
placing both the IVC and the portal vein (see Fig. 1a). A
diagnostic mini-laparotomy by the initial investigating team
resulted in extensive intraoperative bleeding and was incon-
clusive. Subsequent urinary noradrenaline level was found to
be elevated at 787 nmol/24 h (normal range 100–560 nmol/
24 h) with normal urine adrenaline. Chromogranin A was
elevated at 111 nmol/L (normal range 0–60 nmol/L). MIBG
scintigraphy was weakly positive in the abdomen, with no
evidence of metastasis. A diagnosis of multiple PGLs was
made. The invasive left jugular foramen tumor was debulked
under adrenergic blockade, followed by gamma knife radio-
surgery to the residual tumor. A bioplastic injection into the
left vocal cord led to a near-normal voice. Surgical excision of
the abdominal PGLswas deemedhigh riskon the basis of their
proximity to the great vessels. The abdominal PGLs have thus
beenmanagedexpectantly.The subject remains normotensive
on adrenergic blockade with stable abdominal disease over
6 years. Genetic testing confirmed a novelmissense variant of
a G to A base substitution at nucleotide position 338
(c338G[A) in exon 4 of the SDHB gene. Themutation results
in the substitution of the amino acid cysteine for the amino
acid tyrosine at codon 113 (p.Cys113Tyr) [4].
Subject 2
The father of the index subject tested positive for the
familial SDHB mutation following familial screening. He
had a 20-year history of well-controlled hypertension and
an 8-year history of type II diabetes mellitus. Screening CT
imaging at the age of 81 years revealed a 2.8 cm retro-
duodenal mass, most likely a PGL (see Fig. 1b). Five years
of radiological follow-up have shown a stable lesion, and
urinary catecholamines have revealed an intermittently
raised noradrenaline level. Given the patient’s age and the
fact that he was normotensive on alpha blockade without
progressive disease, it was decided to manage the disease
conservatively.
Fig. 1 Imaging from subject 1 demonstrating abdominal and glomus
vagale PGL; subject 2 with an abdominal PGL and subject 3 with a
metastatic PGL involving the aorta
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Subject 3
The son of the index case was found to have elevated urine
and plasma catecholamines on initial surveillance at the age
of 15 years following his father’s diagnosis. He was nor-
motensive (BP 125/68 mmHg), urinary noradrenaline was
elevated at 2863 nmol/24 h (normal range 100–560 nmol/
24 h), and the plasma normetanephrine was elevated at
3575 pmol/L (normal range \1180 pmol/L). Adrenaline
andmetanephrine levelswere normal. AnMRI scan revealed
a single 5.8-cm retroperitoneal left paraaortic mass in the
region of the duodenum, extending from just below the renal
vessels to the level of aortic bifurcation (see Fig. 1c). This
mass demonstrated avid uptake on FDG–PET scan, sug-
gestive of a PGL. He was alpha blocked and consequently
underwent surgery, where the tumor was found to be
invading the aorta bifurcation. Furthermore, a lymph node
inferior to the tumor was found to be involved intraopera-
tively. Aortic resection and insertion of a Dacron graft were
required to fully remove the PGL. He made a good recovery.
Over 4-year follow-up, the urinary metanephrines have been
normal with no evidence of residual disease on radiological
and functional imaging. He has been referred for vascular
follow-up with respect to his aortic graft.
Subject 4
The younger son of the index subject tested positive for the
familial SDHB mutation aged 6 years. He has remained
symptom-free over a 3-year period with no evidence of
PGL on surveillance.
Subject 5
It became clear that disease was present further back in the
family history. The index subject’s grandfather presented
in 1940 at the age of 42 years with abdominal pain on
exertion. Laparotomy for suspected appendicitis was per-
formed, where an ‘inoperable tumor wrapped around the
aorta’ was identified. He was consequently treated with
radiotherapy. He re-presented in 1943 complaining of back
pain and was diagnosed with metastatic disease to the
spine, for which he received spinal radiotherapy. He died at
the age of 46. Though unconfirmed, the likely diagnosis
was metastatic PGL.
Discussion
We have presented a family of five subjects across four gen-
erations all affected byPGLs due to a familialmissense SDHB
mutation. Inactivatingmutations of the SDHB gene are linked
to the familial PGL syndrome type 4 [2]. Germline SDHB
mutations account for an estimated 22–38% of hereditary
pheochromocytomas/PGLs [6, 7]. They are inherited in an
autosomal dominant manner without genomic imprinting, in
contrast to other familial mutations in susceptibility genes,
such as SDHD, where imprinting has been described, and
disease is almost exclusively passed on by the father [8]. The
estimated mean age of onset of disease for hereditary SDHB-
related pheochromocytoma/PGLs is 34 years [9], but docu-
mented cases of malignant PGLs have occurred in childhood
before the age of 10 years [9]. Compared to other familial
paraganglioma syndromes, SDHB-related disease is charac-
terized by low overall penetrance, a more aggressive pheno-
type and significant heterogeneity in presentation [4]. After
correction for ascertainment, the lifetime penetrance of
SDHB-associated disease has been estimated to be approxi-
mately 30% [10], compared to 75% disease penetrance by age
40 in carriers of SDHD mutations [5].
The family described here demonstrates the marked
heterogeneity of disease associated with SDHB mutations.
Despite the same mutation, we note disease presenting
from childhood to old age, an aggressive disease phenotype
in some individuals with local invasive disease and mul-
tiple tumors (subject 1), metastatic disease (subject 3) and
seemingly benign PGL in subject 2. This diversity is
reflected in the individualized management plans ranging
from aggressive tumor debulking to leaving tumors in situ
(subjects 1 and 2). Given the overall low penetrance of
SDHB-related disease, we note that PGLs have presented
in each generation of this family. This may suggest a
mutation-specific preponderance for disease; however, a
lack of clear genotype–phenotype correlation in SDHB
mutations has previously been reported [4].
The diversity in disease characteristics and time of pre-
sentation within this family reiterates the importance of tai-
lored management for each subject. SDHB mutation carriers
require lifelong biochemical and clinical surveillance due to
these variations in presentation and the considerable risk of
metastatic disease. Such patients should be managed by a
multidisciplinary team in a tertiary care setting. In our insti-
tution, a familial PGL clinic runs on a monthly basis in which
families may be seen together and which is supported by the
multidisciplinary team including a clinical nurse specialist,
both adult and pediatric endocrinologists, a radiologist, an
endocrine surgeon and a patient support group. Our current
surveillance regimen includes annual plasma/urinary
metanephrines, annual MRI of the abdomen and 2-yearly
imaging of the neck, thoracic and pelvis. Surveillance starts
from the age of 5 years and may be tailored to the individual
child as tolerated. Intensive surveillance allows disease to be
identified promptly, so that surgery can be instigated early to
affect the natural history of disease (subject 3).
Subjects with SDHB-associated disease present a
specific set of management dilemmas to the clinician—that
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of lowly penetrant disease, but with high metastatic
potential and limited treatment options. Surveillance pro-
grams must allow disease to be identified early while not
over-medicalizing and generating anxiety in carriers who
are unlikely to ever develop disease.
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Table 1 SDHB mutation carriers—disease characteristics
Subject 1
(proband)
Subject 2 Subject 3 Subject 4 Subject 5 (historical case)
Age at first
surveillance













metastasis) ( aged 46)
Biochemistry at
first surveillance
Abnormal Abnormal Abnormal Normal Not available
24 h urine NAdr 1 ? 1 –
24 h urine Adr – – – –
24 h urine Dop – – 1 –
Chromogranin A ? Not available – Not available
Chromogranin B – Not available – Not available
BP at presentation
(mm/Hg)
154/95 187/110 125/68 98/59 Not available
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